These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8727138)

  • 1. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.
    Salazar AM; Levy HB; Ondra S; Kende M; Scherokman B; Brown D; Mena H; Martin N; Schwab K; Donovan D; Dougherty D; Pulliam M; Ippolito M; Graves M; Brown H; Ommaya A
    Neurosurgery; 1996 Jun; 38(6):1096-103; discussion 1103-4. PubMed ID: 8727138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
    Rosenfeld MR; Chamberlain MC; Grossman SA; Peereboom DM; Lesser GJ; Batchelor TT; Desideri S; Salazar AM; Ye X
    Neuro Oncol; 2010 Oct; 12(10):1071-7. PubMed ID: 20615924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
    Giantonio BJ; Hochster H; Blum R; Wiernik PH; Hudes GR; Kirkwood J; Trump D; Oken MM
    Invest New Drugs; 2001; 19(1):89-92. PubMed ID: 11291838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
    Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM
    J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
    Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
    Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
    Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
    Butowski N; Chang SM; Junck L; DeAngelis LM; Abrey L; Fink K; Cloughesy T; Lamborn KR; Salazar AM; Prados MD
    J Neurooncol; 2009 Jan; 91(2):175-82. PubMed ID: 18797818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
    Hartman LL; Crawford JR; Makale MT; Milburn M; Joshi S; Salazar AM; Hasenauer B; VandenBerg SR; MacDonald TJ; Durden DL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):451-7. PubMed ID: 24309609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis.
    Wild JS; Hyde DM; Giri SN
    Pharmacol Toxicol; 1994 Jul; 75(1):42-8. PubMed ID: 7526360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
    Rettenmaier MA; Berman ML; DiSaia PJ
    Gynecol Oncol; 1986 Jul; 24(3):359-61. PubMed ID: 3721308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic guided laser-induced interstitial thermotherapy (SLITT) in gliomas with intraoperative morphologic monitoring in an open MR: clinical expierence.
    Leonardi MA; Lumenta CB
    Minim Invasive Neurosurg; 2002 Dec; 45(4):201-7. PubMed ID: 12494354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
    Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM
    Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
    Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC.
    Wong JP; Yang H; Nagata L; Kende M; Levy H; Schnell G; Blasetti K
    Vaccine; 1999 Mar; 17(13-14):1788-95. PubMed ID: 10194841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
    Pessina GP; Muscettola M; Paulesu L; Bocci V
    J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
    Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
    Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.